<?xml version="1.0" encoding="UTF-8"?>
<p id="Par13">Comparative GO and GSEA analysis revealed that the stromal fraction of M6-Hh tumors are highly enriched for genes encoding ECM processes (Fig. 
 <xref rid="Fig2" ref-type="fig">2b, c</xref>), suggesting that a major influence of paracrine Hh activation on the tumor stroma is related to ECM production and remodeling
 <sup>
  <xref ref-type="bibr" rid="CR18">18</xref>
 </sup>. Genes highly enriched in this set included collagens (
 <italic>Col2a1, Col3a1, Col4a1</italic>, 
 <italic>Col9a1</italic>, 
 <italic>Col11a1</italic>), ECM remodeling metallopeptidases (
 <italic>Mmp3, Mmp13</italic>, 
 <italic>Mmp15</italic>, 
 <italic>Adamts3, Adamts18</italic>), ECM glycoproteins (
 <italic>St8sia2</italic>, 
 <italic>Rspo3</italic>, 
 <italic>Lama5</italic>, 
 <italic>Edil3</italic>, 
 <italic>Thbs4</italic>) and cell adhesion molecules (
 <italic>Cldn3</italic>, 
 <italic>Cldn7</italic>, 
 <italic>Cldn1</italic>, 
 <italic>Cdh2</italic>, 
 <italic>Cdh15</italic>) (Fig. 
 <xref rid="Fig2" ref-type="fig">2c</xref>). Interestingly, these ECM gene expression changes were not a consequence of changes in stromal cellular composition due to Hh pathway activation or long-term SMO inhibition. Immunohistochemical analysis did not reveal any difference between M6-Ctrl and M6-Hh tumors in terms of CAF, endothelial and innate immune cell abundance, regardless of treatment with SMOi (Supplementary Fig. 
 <xref rid="MOESM1" ref-type="media">2a</xref>). This finding was confirmed using whole tumor qRT-PCR and flow cytometry analysis (Supplementary Fig. 
 <xref rid="MOESM1" ref-type="media">2b, c</xref>).
</p>
